Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2
Journal of Clinical Oncology · 10.11.2026 · 44 (32)
DOI: 10.1200/jco-26-01944 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Manish A Shah und 15 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, New York, NY. Hauptthemen laut MEDLINE: Immunotherapy, Stomach Neoplasms, Esophageal Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found on the ASCO Publications website .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Weill Cornell Medicine, New York, NY.
- JSM Research Services, LLC, Arlington, VA.
- American Society of Clinical Oncology, Alexandria, VA.
- Melanoma Research Alliance, Washington, DC.
- Chao Family Comprehensive Cancer Center, University of California-Irvine Medical Center, Irvine, CA.
- Englewood Health, Englewood, NJ.
ORCID-Profile: Manish A Shah, Jacob S Marzalik, Erin B Kennedy, Dana Deighton, Zahra Hamedi, Minaxi Jhawer, Kunal C Kadakia, Paola Montenegro, Sarbajit Mukherjee, Christopher Nevala-Plagemann, Anwaar Saeed, Bryan J Schneider, Thomas Semrad, Kohei Shitara, Lakshmi Rajdev
Zitieren
APA
Shah, M. A., Marzalik, J. S., Kennedy, E. B., Deighton, D., Hamedi, Z., Jhawer, M., Kadakia, K. C., Montenegro, P., Mukherjee, S., Nevala-Plagemann, C., Saeed, A., Schneider, B. J., Semrad, T., Shitara, K., Vincelli, M., & Rajdev, L. (2026). Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2. Journal of Clinical Oncology, 44(32). https://doi.org/10.1200/jco-26-01944
Vancouver
Shah MA, Marzalik JS, Kennedy EB, Deighton D, Hamedi Z, Jhawer M, et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2. Journal of Clinical Oncology. 2026;44(32). doi:10.1200/jco-26-01944
BibTeX
@article{Shah2026,
author = {Shah, Manish A and Marzalik, Jacob S and Kennedy, Erin B and Deighton, Dana and Hamedi, Zahra and Jhawer, Minaxi and Kadakia, Kunal C and Montenegro, Paola and Mukherjee, Sarbajit and Nevala-Plagemann, Christopher and Saeed, Anwaar and Schneider, Bryan J and Semrad, Thomas and Shitara, Kohei and Vincelli, Melani and Rajdev, Lakshmi},
title = {Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {32},
doi = {10.1200/jco-26-01944}
}
EUVIMED